Tech Company Financing Transactions
ARTAN Bio Funding Round
ARTAN Bio secured a $200 million Seed financing round on 6/4/2026. Backers included private investors.
Transaction Overview
Company Name
Announced On
6/4/2026
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to expand its next stage of development, including validation of the suppressor system in animal models, advancement toward a preclinical development candidate, and intellectual property filings to protect the platform's innovations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1101 4th Street. South 300
?St. Petersburg, FL 33701
USA
?St. Petersburg, FL 33701
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
ARTAN is a biotechnology company developing a novel approach to address genetic and age-related diseases caused by nonsense mutations. These mutations lead to premature protein translation stops, resulting in incomplete and nonfunctional proteins. Our pipeline involves an engineered suppressor system that specifically recognizes these codons and restores normal protein translation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony Schwartz
Chief Scientific Officer
Michael Torres
Browse more venture capital transactions:
Prev: 6/4/2026: Manako Labs venture capital transaction
Next: 6/4/2026: Layers venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs